Treatment of Refractory Pyoderma Gangrenosum with Ustekinumab
Keywords:Neutrophilic Dermatosis, Pyoderma Gangrenosum, Ustekinumab, Biologic
Copyright (c) 2022 Nanjiba Nawaz, Marisa Riley, Matthew Helm
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright, simultaneously licensing their works under a Creative Commons Attribution 4.0 International License (CC BY 4.0). That license allows others to share and adapt the work so long as they provide reasonable attribution. This license applies to the submitted version of the work (preprint), the accepted version of the work (postprint), and the final published version.
Ideal attribution for a work published in this journal consists of the work’s title, the title of the journal, the name(s) of the author(s), the DOI (digital object identifier), and a link to the CC BY 4.0 license deed. The journal encourages those relying on the CC BY 4.0 license to consult the Best Practices for Attribution on the Creative Commons wiki.
As they retain copyright, authors are entitled to distribute any version of the article and to grant other licenses to use the work, subject to the CC BY 4.0 license. The journal encourages authors to include the ideal attribution described above when they distribute their works after acceptance by the journal.
Authors are encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and after publication, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see SPARC's "Open Access" article).